Hemab's $300M IPO Funds Phase 3 Push: Rare-Bleeding Breakthrough or Empty Hype?

The IPO Is Funding a Direct Path to Phase 3

Hemab is asking investors to fund a late-stage clinical transition, not just a science story. The company priced its IPO to raise $301.5 million at $18 per share, with another $45 million available if the underwriters exercise the full overallotment. The near-term use of that capital is straightforward: to support a pivotal Phase 3 registration study in 2026 after positive complete Phase 2 data for sutacimig in Glanzmann thrombasthenia. The FDA's Breakthrough Therapy Designation further signals that regulators see meaningful potential in the program.